Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 5,326 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Continuous Dose Clear all
Active, not recruiting Phase 2 Interventional

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

NCT03488667
View directory record Official record
Conditions
Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
Interventions
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Nov 13, 2026, 10:59 PM EST
Completed Phase 2 Interventional Results available

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

NCT00841100
View directory record Official record
Conditions
Phenylketonuria
Interventions
Kuvan, Diet
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
4 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Nov 13, 2026, 10:59 PM EST
Terminated Phase 4 Interventional Results available

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients

NCT01841931
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence, Chronic Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 13, 2026, 10:59 PM EST
Completed Not applicable Interventional Results available

A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy

NCT02979353
View directory record Official record
Conditions
Polypharmacy, Care Transitions, Geriatric Syndromes
Interventions
Shed-Meds: A Patient-Centered Deprescribing Intervention
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Nov 13, 2026, 10:59 PM EST
Terminated Phase 2 Interventional Results available

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

NCT03175172
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
CRS-207, Pembrolizumab
Biological
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Nov 13, 2026, 10:59 PM EST
Completed Phase 1 Interventional Results available

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01562275
View directory record Official record
Conditions
Neoplasms
Interventions
Ipatasertib, Cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Nov 13, 2026, 10:59 PM EST
Terminated Phase 1 Interventional

A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

NCT04017130
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
MT-0169
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 13, 2026, 10:59 PM EST
Completed Phase 2 Interventional

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

NCT00779428
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Tanespimycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Nov 13, 2026, 10:59 PM EST
Terminated Phase 2 Interventional Results available

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

NCT04365257
View directory record Official record
Conditions
COVID-19
Interventions
Prazosin, Standard of care
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Nov 13, 2026, 10:59 PM EST
Terminated Phase 2 Interventional Results available

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease

NCT02245412
View directory record Official record
Conditions
Acute Graft-Versus-Host Disease, GIGVHD
Interventions
ALXN1007 10 mg/kg once weekly, ALXN1007 20 mg/kg once weekly, ALXN1007 20 mg/kg twice weekly
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Nov 13, 2026, 10:59 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study

NCT04774081
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
24h Continuous glucose monitoring and urinary C-peptide collection
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 13, 2026, 10:59 PM EST
Active, not recruiting Phase 2 Interventional

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

NCT02790515
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 13, 2026, 10:59 PM EST
Terminated Phase 2 Interventional Results available

Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer

NCT00564876
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Nov 13, 2026, 10:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

NCT01669291
View directory record Official record
Conditions
Fertility
Interventions
Bravelle and Menopur, Agonist, Antagonist
Drug
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Nov 13, 2026, 10:59 PM EST
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

NCT07472491
View directory record Official record
Conditions
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 13, 2026, 10:59 PM EST
Completed Not applicable Interventional Results available

Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

NCT01093885
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Ambrisentan
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
19 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Nov 13, 2026, 10:59 PM EST
Completed Phase 4 Interventional Results available

Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

NCT04006925
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Parkinson Disease
Interventions
Sodium Oxybate, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Nov 13, 2026, 10:59 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

NCT07242118
View directory record Official record
Conditions
Breast Cancer Female
Interventions
SABR
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 13, 2026, 10:59 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

NCT01919385
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Predictive Low Glucose Minimizer
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Nov 13, 2026, 10:59 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

To Evaluate if the Medication Gabapentin Lessens Vulvar Pain

NCT00390013
View directory record Official record
Conditions
Vulvar Pain Symptoms, Vulvodynia (Chronic Vulvar Pain)
Interventions
Gabapentin, Placebo oral capsule
Drug
Lead sponsor
Colleen Stockdale
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Nov 13, 2026, 10:59 PM EST
Completed Phase 1 Interventional

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

NCT03201913
View directory record Official record
Conditions
Metastatic ER+ Breast Cancer
Interventions
TTC-352
Drug
Lead sponsor
TTC Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Scottsdale, Arizona • Saint Paul, Minnesota • Sioux Falls, South Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 13, 2026, 10:59 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses

NCT02219438
View directory record Official record
Conditions
Healthy Human Volunteers
Interventions
Bolus, Basal
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Nov 13, 2026, 10:59 PM EST
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
ABBV-744, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 13, 2026, 10:59 PM EST
Recruiting Phase 3 Interventional

Vitamin D and Type 2 Diabetes - Treat-To-Target

NCT07448974
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes (T2DM)
Interventions
Vitamin D (Cholecalciferol ), Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years to 74 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 13, 2026, 10:59 PM EST